Rezpegaldesleukin

DB18992InvestigationalProtein Based Therapies

Rezpegaldesleukin is under investigation in clinical trial NCT04433585 (A Study of LY3471851 in Adults With Systemic Lupus Erythematosus (SLE)).

Mechanism: Pharmacologically active on Interleukin-2 receptor subunit beta, Interleukin-2 receptor subunit alpha, and Interleukin-2 receptor
Curator reviewed
Code names: LY-3471851 · NKTR-358

Resolves to

Compound

Targets

What you can answer from here — as of July 16, 2026

3Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

10Clinical trialsPhase, status and sponsor resolved per trial

6+ReferencesStructured and connected to the statements they support

Which drugs share a target with Rezpegaldesleukin, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.